Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren Hodgson(AstraZeneca (United Kingdom)), J. Carl Barrett(National Institute of Environmental Health Sciences), Zhongwu Lai(AstraZeneca (United States)), C. Blake Gilks(Vancouver General Hospital), Kirsten M. Timms(Myriad (Germany)), Lynda Grinsted(AstraZeneca (United Kingdom)), Tony W. Ho(Johns Hopkins University), Mark J. O’Connor(AstraZeneca (United Kingdom)), Anitra Fielding(AstraZeneca (United States)), Jerry S. Lanchbury(Myriad Genetics), Jonathan A. Ledermann(London Cancer), Brian Dougherty(AstraZeneca (United States)), Chris Womack, Jane Robertson(Cancer Research UK), Stuart Spencer(AstraZeneca (United Kingdom)), Maria Orr(AstraZeneca (United Kingdom)), Alexander Gutin(Myriad Genetics), Helen Jones(AstraZeneca (United Kingdom)), Charlie Gourley(Edinburgh Cancer Research)
Cited by 233
Related Papers
A Draft Sequence of the Rice Genome ( <i>Oryza sativa</i> L. ssp. <i>japonica</i> )
|Science|2002|2.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k